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Breast cancer-associated 1 (BRCA1) plays an important role in
breast cancer initiation and progression through its functions in
the cell cycle and DNA repair processes; however, its role in meta-
static development in human breast cancer is still poorly under-
stood. We have previously shown that osteopontin (OPN)
expression was suppressed by wild-type BRCA1 (Wt.BRCA1) and
that a natural mutant allele of BRCA1 (Mut.BRCA1) diminished the
effect of Wt.BRCA1 on OPN in vitro. In this study, we show that
while Wt.BRCA1 suppresses OPN-induced metastasis in a rat syn-
geneic system, Mut.BRCA1 enhances the development of metasta-
sis through OPN, suggesting that OPN and BRCA1 work closely to
regulate metastatic development in the rat. To test whether these
findings are relevant to human breast cancer, we have investi-
gated the relationship between BRCA1, OPN, and metastatic prop-
erties in human breast cancer-related cells. Using western blot
analysis, we show that Wt.BRCA1 suppresses, while Mut.BRCA1
enhances, OPN protein expression; and in parallel that Wt.BRCA1
suppresses, while Mut.BRCA1 enhances, OPN-mediated in vitro
properties associated with the metastatic state in both MCF-7 and
MDA MB435s cells. Overall, these results suggest that Mut.BRCA1
can elicit some of the changes involved in metastatic progression
in human breast cancer via the overexpression of OPN. (Cancer Sci
2010; 101: 1354–1360)
G ermline mutations in the breast cancer-associated 1(BRCA1) gene have been identified in 15–20% of women
with a family history of breast cancer and in 60–80% of women
with a family history of both breast and ovarian cancer,(1) whilst
female mutation carriers have a lifetime breast cancer risk of
60–80%.(2) These results strongly suggest the importance of
studying BRCA1-negative breast cancer. The wild-type BRCA1
(Wt.BRCA1) protein binds to BRCA2, p53, RAD51, and many
other proteins involved in cell cycle and DNA damage
responses(3,4), but how germline mutations in BRCA1 directly
affect the generation of the malignant phenotype and the devel-
opment of metastasis is largely unknown. One such intermediary
in the rat has been suggested to be osteopontin (OPN).(5)
Osteopontin is an extracellular glycophosphoprotein,(6,7)
which is important in malignant transformation in vitro, enhanc-
ing cell properties, such as attachment to extracellular matrixes,
migration, and invasion.(8–11) Its production has also been shown
to provide prognostic value to breast cancer progression.(12–14)
We have previously shown, in the rat mammary cell line Rama
37,(15) that Wt.BRCA1 represses the expression of this estrogen-
responsive gene.(5) In this rat cell system, Wt.BRCA1 also
inhibits OPN-mediated malignant transformation in vitro, while
a natural mutant BRCA1 (Mut.BRCA1), which is associated
with familial breast cancer,(16) lacks this OPN suppressive effect
and impedes Wt.BRCA1 suppression of expression of OPN.(5)
We now investigate the effects of Wt. and the Mut.BRCA1 on
the metastatic potential of the rat mammary cells in syngeneic
rats in vivo and upon OPN-mediated cellular properties indica-
tive of malignant transformation of human breast cancer-related
cell lines in vitro. The Mut.BRCA1 promotes metastasis in rats
in vivo and malignant transformation of human breast cancer-
related cells in vitro by increasing the expression of OPN.
Materials and Methods
Plasmids and oligonucleotides. Expression vectors for human
Wt.BRCA1 and Mut.BRCA1 in the Rc ⁄CMV vector have been
described previously.(5) The Mut.BRCA1 encodes a point muta-
tion (Ala-1708 ﬁ Glu) in its C-terminal region, This is a
germline mutation associated with very early onset familial
breast cancer.(16)
Cell lines and cell culture. See the Appendix S1.
Stable and transient transfections. Permanently expressing
OPN cells were produced by transfection of the expression vec-
tor for OPN, for OPN antisense mRNA (as-OPN), or the empty
expression vector pBK-CMV into Rama 37, MCF-7, and MDA
MB435s cells, as described previously(5) (see Appendix S1).
Western blotting for proteins. Detection of BRCA1 or OPN
proteins were performed using a rabbit polyclonal antibody to
BRCA1 which can detect both human and rat (sc-7867; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and a mouse mono-
clonal antibody (mAb) MBIII B10 to OPN (Developmental Stud-
ies Hybridoma Bank, University of Iowa, Iowa City, IA,
USA)(13) as described previously.(5)
Soft-agar, cell-substrate adhesion, and Matrigel invasion
assays.(17) See the Appendix S1.
Assays for metastasis. Stable transfectants were harvested by
treatment with EDTA ⁄ trypsin solutions, and washed and resus-
pended in PBS at 107 cells ⁄mL. Two · 106 cells in 0.2 mL
were injected s.c. through the skin into the right inguinal fat
pads of 6- to 10-week-old syngeneic female Furth–Wistar rats
(Ludwig–Wistar OLA strain), usually 20 rats ⁄group.(15) Rats
were autopsied after 12 weeks, and tumors and relevant tissues,
particularly the lungs and lymph nodes, were examined for gross
metastases. Primary tumors and other tissues of abnormal
appearance including all lungs were fixed in methacarn (metha-
nol, inhibisol, acetic acid: 6, 3 ,1), embedded in paraffin-wax,
sectioned, and stained with hematoxylin–eosin. Five micro-
scopic fields from two sections for the primary tumor and for
the lungs were assessed for microscopically visible metastases
by the independent observers, as described previously.(18,19)
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Immunocytochemical staining for BRCA1 and for OPN was
performed as described previously.(5,13) Photographs were
recorded in a Polyvar microscope (Reichert, Depew, NY, USA)
fitted with Hoya 80A plus 80B filters (Hoya, Santa Clara, CA,
USA) on Kodak Gold 200ASA color film (Kodak, New York,
NY, USA).
Luciferase reporter assay.(5) See the Appendix S1.
Results
Effect of permanent transfection of BRCA1 on metastasis in vivo
in a syngeneic rat model system. Rama 37 (R37) stable transfec-
tants R37 ⁄pBK-CMV, R37 ⁄OPN, R37 ⁄Wt.BRCA1, R37 ⁄Mut.
BRCA1, R37 ⁄ as-OPN, R37 ⁄OPN ⁄ as-OPN, R37 ⁄ as-OPN ⁄Mut.
BRCA1, and R37 ⁄OPN ⁄Wt.BRCA1 were produced from pooled
clones of transfectants. When injected into syngeneic rats, there
was no significant difference in the incidence of tumors for any
of the transfected pooled cells (Fisher’s exact test, P ‡ 0.16,
Table 1). Only R37 ⁄OPN (P = 0.00001) and R37 ⁄Mut.BRCA1
(P = 0.0004) pooled cells induced a significant increase in the
occurrence of metastases (65% and 50%, respectively) when
injected into the rats compared to the control R37 ⁄pBK-CMV
pooled cells (0%). No metastases were found when the rats were
injected with R37 ⁄Wt.BRCA1 cells (Table 1). When the synge-
neic rats were injected with R37 ⁄OPN cells transfected with
expression vector for Wt.BRCA1, the incidence of metastasis
was significantly reduced (P = 0.003) to 9.5% (Table 1). More-
over, R37 ⁄OPN ⁄ asOPN and R37 ⁄ asOPN ⁄Mut.BRCA1 cells
injected into the syngeneic rats produced significantly fewer
metastases than their OPN-overexpressing counterparts (12%
and 6%, respectively; P = 0.004; 0.006). Indeed, the number of
rats with metastases produced in this condition was not signi-
ficantly different from the vector control-transfected cells. The
difference in the incidence of metastases between R37 ⁄OPN and
R37 ⁄Mut.BRCA1 cells (P = 1) and between any of R37 ⁄pBK-
CMV, R37 ⁄Wt.BRCA1, R37 ⁄OPN ⁄ as-OPN, and R37 ⁄ as-OPN ⁄
Mut.BRCA1 cells (P ‡ 0.32) was not significant (Table 1). The
majority of the metastases occurred in the lungs (Fig. 1a), with a
few metastases in the lymph nodes, but no metastatic deposits
were observed in other organs.
The histological appearance of primary tumors and any
metastases from all of the six groups were similar, primarily
consisting of spindle cells admixed with more cuboidal, epithe-
lial-like cells (Fig. 1a,b). Immunocytochemical staining for
BRCA1 confirmed that R37 ⁄Mut.BRCA1 and R37 ⁄ as-OPN ⁄
Mut.BRCA1 cells overproduced a BRCA1-related molecule in
the lung metastases (Fig. 1a) and primary tumors (Fig. 1b) in
Table 1. Incidence of tumors and metastases produced by
transfected rat mammary cells
Transfected cells*
Tumor
incidence (%)†
Incidence of
metastasis (%)‡
R37 ⁄ pBK-CMV 20 of 20 (100) 0 of 20 (0)
R37 ⁄OPN 17 of 20 (85) 11 of 17 (65)**
R37 ⁄Wt.BRCA1 25 of 25 (100) 0 of 25 (0)
R37 ⁄Mut.BRCA1 20 of 20 (100) 10 of 20 (50)**
R37 ⁄OPN ⁄ as-OPN 17 of 20 (85) 2 of 17 (12)
R37 ⁄ as-OPN ⁄Mut.BRCA1 18 of 20 (90) 1 of 18 (6)
R37 ⁄OPN ⁄Wt.BRCA1 21 of 22 (96) 2 of 21 (9.5)
*Pools of clones of Rama 37 (R37) cells transfected with the
expression vector alone pBK-CMV (R37 ⁄ pBK-CMV) or with the
expression vectors for the following: osteopontin (OPN) (R37 ⁄OPN),
wild-type breast cancer-associated 1 (BRCA1) (R37 ⁄Wt.BRCA1), mutant
BRCA1 (R37 ⁄Mut.BRCA1), osteopontin and antisense construct to OPN
mRNA (R37 ⁄OPN ⁄ as-OPN), antisense construct to OPN mRNA and
mutant BRCA1 (R37 ⁄ as-OPN ⁄Mut.BRCA1), and osteopontin and wild-
type BRCA1 (R37 ⁄OPN ⁄Wt.BRCA1). †Tumor incidence = number of
tumors ⁄ number of rats inoculated. Tumor incidence of all the cells
transfected with the expression vectors for different proteins was not
significantly different from that of vector alone–transfected cells
(Fisher’s exact test, P ‡ 0.16). ‡Incidence of metastasis = number of
rats with lung metastases ⁄ number of rats with tumors. **Significantly
different from R37 ⁄ pBK-CMV expression vector alone controls and
from R37 ⁄Wt.BRCA1, R37 ⁄OPN ⁄ as-OPN, R37 ⁄ as-OPN ⁄Mut.BRCA1, and
R37 ⁄OPN ⁄Wt.BRCA1 cells (Fisher’s exact test, P £ 0.03). There was no
significant difference between R37 ⁄OPN and R37 ⁄Mut.BRCA1 cells
(P = 1), and between R37 ⁄ pBK-CMV, R37 ⁄Wt.BRCA1, R37 ⁄OPN ⁄
as-OPN, R37 ⁄ as-OPN ⁄Mut.BRCA1, and R37 ⁄OPN ⁄Wt.BRCA1 cells
(Fisher’s exact test, P ‡ 0.32).
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Fig. 1. Immunocytochemical staining of primary tumors and
metastases produced by pools of Rama 37 (R37) transfectants in the
rat. (a) Lung metastases produced by R37 ⁄Mut.BRCA1 (mutant breast
cancer-associated 1) pooled cells incubated with antibodies to BRCA1
showing strong red nuclear (arrow) and weaker red cytoplasmic
(arrowhead) staining. (b) Primary tumor produced by R37 antisense
osteopontin (as-OPN) ⁄Mut.BRCA1 pooled cells incubated with
antibodies to BRCA1 showing strong red nuclear (arrow) and weaker
red cytoplasmic staining (arrowhead). (c) Primary tumor produced by
R37 ⁄OPN pooled cells showing little nuclear and a very weak reddish
cytoplasmic staining (arrowhead) for BRCA1. (d) Cannon ball lung
metastasis produced by R37 ⁄Mut.BRCA1 pooled cells incubated with
antibodies to OPN showing strong red staining of the malignant cells
(arrow) and no staining of the parenchymal lung tissue (arrowhead).
(e) More diffuse lung metastasis produced by R37 ⁄Mut.BRCA1 pooled
cells incubated with antibodies to OPN showing strong cytoplasmic
(arrowhead) and pericellular (arrow) red staining of the malignant
cells. (f) Primary tumor produced by R37 ⁄Wt.BRCA1 pooled cells
showing no staining for OPN. (g) More diffuse lung metastasis
produced by R37 ⁄OPN pooled cells showing cytoplasmic (arrows) and
pericellular (arrowheads) red staining of the malignant cells for OPN.
(h) Primary tumor produced by R37 ⁄ as-OPN ⁄Mut.BRCA1 pooled cells
showing no staining for OPN. Magnification: (a, c, e, f) ·580; (b) ·720;
(d) ·230; (g,h) ·460. Bar: 20 lm (a–c, e,f); 50 lm (d); 25 lm (g,h). In all
sections cell nuclei were counterstained blue by hemalum.
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comparison with primary tumors produced by injection of
R37 ⁄OPN cells (Fig. 1c). The resultant staining was predo-
minantly nuclear with lesser staining in the cytoplasm in the
Mut.BRCA1-transfected cells (Fig. 1a,b), whereas BRCA1
staining in the R37 ⁄OPN cells was much weaker and mainly
cytoplasmic (Fig. 1c). The R37 ⁄Mut.BRCA1 cells produced
immunocytochemically detectable OPN in both cannon ball
(Fig. 1d) and more diffuse (Fig. 1e) lung metastases, whereas
no immunologically detectable OPN was observed in the pri-
mary tumors produced by R37 ⁄Wt.BRCA1 cells (Fig. 1f). The
cannon ball and the more diffuse lung metastases produced by
R37 ⁄Mut.BRCA1 cells (Fig. 1e) and by R37 ⁄OPN cells were
similar (Fig. 1g); the staining for OPN was cytoplasmic and
pericellular with no staining of cellular nuclei (Fig. 1e,g). In
contrast, R37 ⁄ as-OPN ⁄Mut.BRCA1 cells produced primary
tumors that stained weakly for OPN (Fig. 1h). These results
suggest that the primary tumors and the resultant metastases
contain the genetic modifications we have introduced in vitro
and are a result of the injection of the corresponding Rama 37
derivatives.
Effect of BRCA1 on OPN gene expression in human breast
cancer cells. To investigate whether our findings in rat mam-
mary epithelial cells are applicable to human breast cancer
development, we modulated the expression levels of Wt.
BRCA1, Mut.BRCA1, and OPN in human breast cancer cell
lines MDA MB435s and MCF-7. Immunoblots using a poly-
clonal antibody to the BRCA1 N-terminal region indicated
similar elevated levels of BRCA1 protein in MDA
MB435s ⁄Wt.BRCA1 and MDA MB435s ⁄Mut.BRCA1 cells
(5- and 5.2-fold, respectively) over the control untransfected
MDA MB435s cells (Fig. 2a). A similar and approximately
equal pattern of BRCA1 levels were observed in MCF-7 ⁄Wt
and Mut.BRCA1 cells (3.4- and 3.2-fold, respectively)
(Fig. 2c).
OPN protein levels were found to be reduced fivefold in
MDA MB435s ⁄Wt.BRCA1 cells but increased 3.4-fold in MDA
MB435s ⁄Mut.BRCA1 cells compared to control MDA MB435s
cells (Fig. 2a). Mut.BRCA1 expressing MCF-7 cells produced
8.3-fold higher OPN protein levels than MCF-7 cells alone
(Fig. 2c). When the MDA MB435s and MCF-7 cells were stably
transfected with an expression vector for OPN, they produced a
2.5- (P = 0.006) and 3.9- (P = 0.0001) fold increase in OPN
protein, for the MDA MB435s ⁄OPN and MCF-7 ⁄OPN cells,
respectively (Fig. 2b,d). In the BRCA1 expression vector-trans-
fected, OPN-overexpressing cells, Wt.BRCA1 inhibited OPN
protein by approximately 13- (P = 0.001) and 3- (P = 0.0002)
fold in MDA MB435s ⁄OPN and in MCF-7 ⁄OPN cells, respec-
tively, while Mut.BRCA1 produced little (P = 0.03) or no
(P = 0.49) significant effect on OPN protein levels (Fig. 2b,d).
These data were obtained with pools of transfected cell clones,
but similar results were obtained with two single clones of trans-
fected cells (not shown). In all cases, BRCA1 and OPN protein
levels were normalized against constitutively expressed b-actin
in the same protein samples (Fig. 2a–d). Transfection of MDA
MB435s and MCF-7 cells with an expression vector for as-OPN
reduced OPN protein levels by 76% (P < 0.0001) and 20%
(P = 0.03), respectively, compared to untransfected cells
(Fig. 2b,c). Transfection of MDA MB435s ⁄ as-OPN and MCF-
7 ⁄ as-OPN cells with an expression vector for Mut.BRCA1 pro-
duced no (P ‡ 0.57) significant increase in levels of OPN
(Fig. 2b,c). Transient transfection of MDA MB435s ⁄Wt.BRCA1
and MCF-7 ⁄Wt.BRCA1 cells with an expression vector for
Mut.BRCA1 significantly induced OPN protein expression by
18- (P = 0.0001) and 13- (P = 0.0001) fold, respectively,
restoring them to levels observed with Mut.BRCA1 (Fig. 2a–d).
These results suggest that OPN expression can be regulated in a
negative and positive manner by Wt. and Mut.BRCA1, respec-
tively, in human breast cancer-related cell lines in culture.
We have previously shown, in a rat mammary cell line, that
BRCA1 binds to transactivating transcription factors of OPN,
such as Pea3 and c-Jun, to down-regulate OPN expression, while
mutant BRCA1 up-regulates OPN.(5) To investigate whether
Wt.BRCA1 and Mut.BRCA1 behave similarly in human breast
cancer, we cloned the human OPN promoter into pGL-3 lucifer-
ase reporter construct and co-transfected this construct with vec-
tor control, Wt.BRCA1 expression vector, or both Wt.BRCA1
and Mut.BRCA1 expression vectors. Similar to our previous
findings, Wt.BRCA1 suppressed the human OPN promoter by
29 ± 2% (P = 0.009), while Mut.BRCA1 abolished the suppres-
sive effect of Wt.BRCA1 on the human OPN promoter
(Fig. 2e). This result suggests that BRCA1 suppresses OPN
expression by inhibiting OPN promoter activity and that this
suppression was reversed by Mut.BRCA1. Recent studies on
MDA MB435s cells have revealed uncertainty regarding the
breast origin of this cancer cell line.(20,21) We therefore con-
firmed the results in another breast cancer cell line, MDA
MB468, which expresses OPN, though in relatively low levels
compared to MDA MB435 cells (data not shown). Overexpres-
sion of Wt.BRCA1 in MDA MB468 cells resulted in increased
mRNA and protein levels of BRCA1 (Fig. S1). Overexpression
of Wt.BRCA1 on MDA MB468 cells resulted in a significant
91% (P < 0.0001) reduction in mRNA levels (Fig. S1b), as well
as a significant 23% (P = 0.02) reduction in protein levels of
OPN (Fig. S1c). These results confirm that Wt.BRCA1 plays an
important role in expression of OPN in human breast cancer-
related cells.
Effect of BRCA1 on anchorage-dependent and independent
growth in human breast cancer cells. Transfectants of MDA
MB435s and MCF-7 cells overexpressing Wt.BRCA1,
Mut.BRCA1, or OPN showed little or no changes in their
respective proliferation rates in culture (data not shown). When
MDA MB435s or MCF-7 cells were transfected with an expres-
sion vector for Wt.BRCA1 and assayed in soft agar, the colony
number per plate was reduced by 63% (Student’s t-test,
P = 0.0001) (Fig. 3a) and 20% (P = 0.074) (Fig. 4a), respec-
tively. Overexpression of Mut.BRCA1 produced no change in
the number of colonies formed in MDA MB435s cells (Fig. 3a),
while it significantly increased the number of colonies formed in
MCF7 cells by 6.5-fold (P = 0.0004) (Fig. 4a). Similarly, over-
expression of OPN produced only little change in the number of
colonies formed in MDAMB 435s (Fig. 3a), but it increased the
number of colonies formed by 7.5-fold in MCF-7 cells
(P = 0.0001) (Fig. 4a). Furthermore, Wt.BRCA1, but not
Mut.BRCA1, suppressed the colony-forming ability of OPN-
overexpressing MDA MB435s (Fig. 3a) and MCF7 cells
(Fig. 4a). When the expression of OPN was silenced by anti-
sense OPN, there was a significant 5.3-fold decrease in the num-
ber of colonies formed in MDA MB435s cells (P = 0.0001)
(Fig. 3a) but not in MCF7 cells (Fig. 4a), which express only
low levels of endogenous OPN. Transfection of MDA
MB435s ⁄ as-OPN or MCF-7 ⁄ as-OPN cells with an expression
vector for Mut.BRCA1 did not affect colony formation
(P = 0.75, 0.9, respectively) (Figs 3a,4a). However, transient
transfection of MDA MB435s ⁄Wt.BRCA1 or MCF-
7 ⁄Wt.BRCA1 cells with an expression vector for Mut.BRCA1
significantly increased the number of colonies formed by 3-
(P = 0.0001) or 9- (P = 0.0003) fold (Figs 3a,4a), respectively,
restoring them to similar levels of MDA MB435s or MCF-
7 ⁄OPN cells. Similarly MDAMB 468 cells overexpressing
Wt.BRCA1 produced 41% fewer colonies (P = 0.03, Fig. S1d)
compared to the vector control cells.
Effect of BRCA1 on adhesion and invasion in human breast
cancer cells. When parental MDA MB435s cells were transfect-
ed with an expression vector for Wt.BRCA1, the resultant cell
adhesion and invasion values were reduced by 2.4-fold
(Student’s t-test, P = 0.0001) and 2.6-fold (P = 0.006),
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respectively. Transfection of MDA MB435s with an expression
vector for Mut.BRCA1 produced no significant difference in cell
adhesion and invasion (Fig. 3b,c). Transfection of MDA
MB435s cells with an expression vector for OPN increased cell
adhesion and invasion by a modest 1.5- and 1.3-fold, respec-
tively (P = 0.001, P = 0.01) (Fig. 3b,c). Transfection of MDA
MB435s ⁄OPN cells with an expression vector for Wt.BRCA1,
but not that for Mut.BRCA1, reduced cell adhesion and invasion
by 2.9- and 2.8-fold, respectively (P = 0.0003, P = 0.0002)
(Fig. 3b,c). In contrast to MDA MB435s cells, transfection of
MCF-7 cells with an expression vector for Mut.BRCA1, but not
that for Wt.BRCA1, increased cell adhesion by 2.7-fold
(P = 0.0001) and invasion by 5.1-fold (P = 0.001) (Fig. 4b,c).
Moreover, transfection of MCF-7 cells with an expression vec-
tor for OPN increased cell adhesion and invasion by 2.8- and
5.7-fold, respectively (P = 0.002, 0.001). Further transfection of
these MCF-7 ⁄OPN cells with an expression vector
for Wt.BRCA1 reduced cell adhesion and invasion by 2.5- and
4.2-fold, respectively (P = 0.002, P = 0.0005) (Fig. 4b,c). Sim-
ilarly, MDA MB468 cells overepressing Wt.BRCA1 were 22%
(a) (b) (c)
(d) (e)
Fig. 2. Expression studies in MDA MB435s and MCF-7 pooled transfectants. Breast cancer-associated 1 (BRCA1) and osteopontin (OPN) protein
expression levels were recorded by immunoblot for wild-type (Wt.BRCA1), mutant BRCA1 (Mut.BRCA1), and OPN in either (a,b) MDA MB 435s-
related cells or in (c,d) MCF-7-related cells. A representative blot of three experiments is shown. Bands were quantified using densitometric
analysis, normalized against b-actin and standardized with respect to the level of their parental control cells. The average fold increase ± SD for
three different experiments is shown on a histogram. (e) Osteopontin promoter activity was measured by firefly luciferase reporter activity
normalized to Renilla luciferase activity with same cells (see ‘Material and Methods’).
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less adhesive compared to the vector control cells (P = 0.004)
(Fig. S2e).
When MDA MB435s cells were transfected with the construct
for as-OPN, cell adhesion and invasion were reduced by 2.5-
and 4.1-fold, respectively (P = 0.0001, 0.001) (Fig. 3b,c), while
there was no significant effect of the same construct for as-OPN
on MCF-7 cell adhesion or invasion (P ‡ 0.9) (Fig. 4b,c).
Transfection of MDA MB 435s ⁄ as-OPN or MCF-7 ⁄ as-OPN
cells with an expression vector for Mut.BRCA1 showed no sig-
nificant changes in cell adhesion or invasion (P ‡ 0.9)
(Figs 3b,c, 4b,c). In contrast, transient transfection of MDA MB
435s ⁄Wt.BRCA1 or MCF-7 ⁄Wt.BRCA1 cells with an expres-
sion vector for Mut.BRCA1 increased cell adhesion by 2.9- or
2.6-fold, respectively (P = 0.004, 0.002) (Fig. 3b,4b) and inva-
sion by 2.7- or 6.8-fold, respectively (P = 0.002, 0.001)
(Fig. 3c,4c).
Discussion
Previously, we have shown the interaction in vitro between
BRCA1 and a well-established inducer of malignant metastatic
spread in a rat mammary modal cell line system,(5) OPN. Osteo-
pontin itself is thought to induce metastasis by its activity to pro-
mote ‘‘inter alia’’ anchorage independent growth, cell adhesion,
and cell invasion,(6–11) and its expression in human breast cancer
is associated with patient death from metastatic disease.(12–14) In
the present study, we have further confirmed the results in the
rat model system by observation of induction of metastasis
in vivo by Mut.BRCA1 but not by Wt.BRCA1. This metastasis-
inducing effect of Mut.BRCA1 depends on OPN, since trans-
fection of an as-OPN construct to OPN mRNA into
Fig. 3. Effects of overexpression of breast cancer-associated 1
(BRCA1), mutant BRCA1 and osteopontin (OPN) on properties
associated with the malignant state of MDA MB435s cells in vitro
were investigated by (a) soft agar, (b) cell adhesion, and (c) cell
migration assays as described in the Material and Methods.
Fig. 4. Effects of overexpression of breast cancer-associated 1
(BRCA1), mutant BRCA1, and osteopontin (OPN) on properties
associated with the malignant state of MCF-7 cells in vitro were
investigated by (a) soft agar, (b) cell adhesion, and (c) cell migration
assays as described in the Material and Methods.
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R37 ⁄Mut.BRCA1 cells significantly reduces the incidence of
metastasis to a level similar to that for the R37 ⁄vector control
cells (Table 1). The changes in incidences of metastasis are unli-
kely to be due to alterations in cell proliferation rates, as these
are not significantly different between all the R37 derivatives
described in the present study. Moreover the histology of the
lung metastases produced by injection into the rat mammary fat
pad of either R37 ⁄Mut.BRCA1 or R37 ⁄OPN cells and their cel-
lular content ⁄distribution of immunoreactive OPN are very simi-
lar (Fig. 1d,e,g), suggesting that the development of metastases
is mainly due to overexpression of OPN. Primaries which fail to
overexpress OPN also fail to metastasize (Fig. 4f,h). The results
from the in vivo study suggest that Mut.BRCA1 promotes devel-
opment of metastases through up-regulation of OPN protein lev-
els and that Wt.BRCA1 counteracts the metastasis-inducing
effect of OPN overexpression, suggesting that BRCA1 works
closely with OPN in development of metastasis.
To investigate whether our findings are applicable to the
human cancer metastatic development, we have tested our
hypothesis also in the human cell lines MDA MB435s and
MCF7. Although both MDA MB435s and MCF-7 cell lines
were derived from breast cancers, the MDA MB435s cells are
more aggressive than MCF-7 cells, insofar as MDA MB435s
cells possess the ability to form metastases in immunodeficient
mice,(22) an ability which the unsupplemented MCF-7 cells nor-
mally lack in vivo.(23) Knockdown of OPN in MDA MB435s
cells reduces, and overexpression of OPN in MCF-7 cells
increases, colony formation, cell adhesion, and invasion in vitro,
suggesting that OPN plays an important role in metastatic
behavior in these two cell lines at least in vitro.
The inhibitory effect of Wt.BRCA1 on in vitro malignant
properties of MCF-7 ⁄OPN cells and MDA MB435s cells is
probably exerted by a lowering of the level of OPN protein. The
fact that transfection of MDA MB435s ⁄OPN and MDA
MB435s cells with an expression vector for Wt.BRCA1 reduces
OPN and in vitro malignant properties to similar levels suggests
that expression from the endogenous and transgenes for OPN
are both suppressed by Wt. BRCA1. It is postulated that BRCA1
may regulate OPN protein levels post-transcriptionally, since
post-transcriptional regulation of OPN expression has been
reported previously.(24,25) However, we have shown that
Wt.BRCA1 suppresses the endogenous mRNA for OPN by 91%
in the MDA MB468 cells (Fig. S1b) and that the promoter activ-
ity of human OPN is reduced by 29% when transfected into
MDA MB435s cells (Fig. 2e). These results suggest that much
of the reduction in production of OPN protein may be due to
inhibition of transcription of the endogenous OPN gene possibly
at its promoter, as we have found in detail in the rat mammary
model systems.(5)
To gain insight into the mechanism whereby BRCA1 sup-
presses and Mut.BRCA1 reverses and stimulates OPN transcrip-
tion, we have shown in previous publications in the rat
mammary cells that Wt.BRCA1 is able to suppress estogen
receptor-a (ERa), c-jun, and Pea3 transcription factor transacti-
vation of the rat OPN promoter-reporter construct.(5) The human
OPN promoter isolated here contains recognition sequences for
these same transcription factors (El-Tanani M.K., unpublished
results), suggesting that these factors would also be operational
on the human OPN promoter in vitro.(26,27) This suggestion is
consistent with our previous reports where the expression of
human OPN was significantly associated with the presence
of these transcription factors in primary breast carcinomas
in vivo.(26,27) The surprising result that Wt.BRCA1 also sup-
presses expression of exogeneously produced OPN in both
MDA MB435s and MCF-7 cells (Fig. 2b,d) may be due to the
fact that the OPN transgene has been placed under the control of
the CMV promoter which contains a major core of 11 and three
recognition sequences for c-jun and Ets transcription factors,
respectively.(5) Moreover, we have suggested that BRCA1 may
inhibit OPN expression ‘‘inter alia’’ by specifically binding to
these three transcription factors, as demonstrated in broken cell
extracts and in that Mut.BRCA1 inhibits this process by its
capability of binding to Wt.BRCA1 in a dominant negative
manner.
In conclusion, human and rat breast cancer-related cell lines
have been used in the present study to show that Mut.BRCA1
can promote metastatic progression both in vitro and in vivo,
respectively, via the overexpression of a metastasis-inducing
protein, OPN. This result is consistent with the appearance of
enhanced expression of OPN in a group of familial primary
breast cancers with mutant BRCA1, in comparison with that
found in sporadic breast cancers containing wild-type
BRCA1.(5) Moreover, we have found that Mut.BRCA1 promotes
metastatic progression in vitro regardless of the expression sta-
tus of Wt.BRCA1. Single copies of mutated BRCA1 and
BRCA2 have been shown to confer as high as an 80% likelihood
of developing breast cancer(28) while mutant BRCA1 allele has
been shown to function in a dominant negative manner.(5,29) Our
results suggest that Mut.BRCA1 might promote metastatic pro-
gression of human breast cancer cells through suppressing the
Wt.BRCA1-inhibited OPN expression in a dominant negative
manner.
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Supporting Information
Additional Supporting Information may be found in the online version of this article:
Appendix S1. Supplementary Materials and Methods.
Fig. S1. The suppressive effect of breast cancer-associated 1 (BRCA1) on osteopontin (OPN) was confirmed in another breast cancer cell line
MDA MB468, which expresses OPN but low levels of BRCA1. (a) BRCA1 mRNA expression levels were increased in MDA MB468 ⁄Wt.BRCA1
compared to vector alone-transfected MDA MB468 cells. Osteopontin (b) mRNA and (c) protein levels were reduced in Wt.BRCA1-transfected
MDA MB468 cells. Both (d) colony formation and (e) cell adhesion were reduced in MDA MB468 cells with higher levels expression of
BRCA1.
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